Anthropic to develop its own pharmaceuticals

Anthropic plans to develop its own drugs rather than just providing AI tools for pharmaceutical companies, according to a report from STAT News.
This move follows the launch of Claude Science, a workspace built for life science researchers. Anthropic is now shifting from a tool provider to an active participant in drug development.
Specific program details and therapeutic focus areas have not yet been disclosed.
Up next
Claude Desktop turned into a C2 agent via configuration poisoning
Pentera Labs injected a base64 prompt into Claude Desktop settings, which synced to all victim devices. Claude then acted as a persistent C2 channel, running bash commands sent by the attacker. Anthropic maintains this is not a vulnerability, as settings and MCP connectors are designed to execute code.
Related stories
- Anthropic paid $740,000 to a firm led by Rubio’s ex-aide
- CNBC: Anthropic IPO likely to price above $70-78
- Microsoft shares slid as Claude got Sheets and Whiteboards
- WSJ: Anthropic on Trump’s list of AI national champions
- Anthropic plans Wednesday IPO at $1.4 trillion
- Anthropic bought a biotech with one full-time employee
Comments
No comments yet. Be the first.
Join the conversation
Sign in to leave a comment. It appears after moderation.

